Compare AU

Compare CURE vs. IPAY

Compare shares and ETFs on the ASX that you can trade on Pearler.

S&P US Biotech

ASX

Buy

Buy

Overview
Performance

Overview

When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the S&P US Biotech (CURE) and the BetaShares Future of Payments ETF (IPAY). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.

Community Stats

CURE

IPAY

Popularity

Low

Low

Pearlers invested

83

5

Median incremental investment

$619.50

$516.50

Median investment frequency

Monthly

Monthly

Median total investment

$1,461.60

$1,413.00

Average age group

> 35

> 35


Key Summary

CURE

IPAY

Strategy

CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

IPAY.AX was created on 2021-12-13 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. IPAY.AX aims to track the performance of an Index (before fees and expenses) that provides exposure to a

Top 3 holdings

Natera Inc (3.33 %)

Incyte Corp (2.95 %)

Gilead Sciences Inc (2.81 %)

FISERV INC (6.13 %)

AMERICAN EXPRESS CO (6.09 %)

MASTERCARD INC (5.72 %)

Top 3 industries

Health Care (100.00 %)

Other (10.24 %)

Financials (80.85 %)

Other (15.00 %)

Information Technology (4.15 %)

Top 3 countries

United States (97.17 %)

Switzerland (1.51 %)

United Kingdom of Great Britain and Northern Ireland (1.16 %)

United States (82.97 %)

Netherlands (4.72 %)

United Kingdom of Great Britain and Northern Ireland (3.47 %)

Management fee

0.45 %

0.67 %


Key Summary

CURE

IPAY

Issuer

Global X

BetaShares

Tracking index

S&P Biotechnology Select Industry

Nasdaq CTA Global Digital Payments Index - AUD - Benchmark TR Net

Asset class

ETF

ETF

Management fee

0.45 %

0.67 %

Price

$52.20

$14.13

Size

$36.301 million

$2.998 million

10Y return

N/A

N/A

Annual distribution yield (5Y)

4.24 %

- %

Market

ASX

ASX

First listed date

12/11/2018

14/12/2021

Purchase fee

$6.50

$6.50


Community Stats

CURE

IPAY

Popularity

Low

Low

Pearlers invested

83

5

Median incremental investment

$619.50

$516.50

Median investment frequency

Monthly

Monthly

Median total investment

$1,461.60

$1,413.00

Average age group

> 35

> 35


Pros and Cons

CURE

IPAY

Pros

  • Higher exposure to US market

  • Lower management fee

  • Higher distribution yield

  • Higher exposure to AU market

  • Higher price growth

Cons

  • Lower exposure to AU market

  • Lower price growth

  • Lower exposure to US market

  • Higher management fee

  • Lower distribution yield

CURE

IPAY

Lower exposure to AU market

Higher exposure to AU market

Higher exposure to US market

Lower exposure to US market

Lower management fee

Higher management fee

Lower price growth

Higher price growth

Higher distribution yield

Lower distribution yield

Home